Antitrust in Pharmaceutical Markets & Geographical Rules of Origin

Antitrust in Pharmaceutical Markets & Geographical Rules of Origin
Author :
Publisher : Springer
Total Pages : 499
Release :
ISBN-13 : 9783319558134
ISBN-10 : 3319558137
Rating : 4/5 (37 Downloads)

Book Synopsis Antitrust in Pharmaceutical Markets & Geographical Rules of Origin by : Pierre Kobel

Download or read book Antitrust in Pharmaceutical Markets & Geographical Rules of Origin written by Pierre Kobel and published by Springer. This book was released on 2017-09-20 with total page 499 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book gathers international and national reports from across the globe on key questions in the field of antitrust and intellectual property. The first part discusses the application of competition law in the pharmaceutical sector, which continues to be a focus for anti-trust authorities around the world. A detailed international report explores the extent to which the application of the competition rules in the pharmaceutical sector should be affected by the specific characteristics of those products and markets (including consumer protection rules, the need to promote innovation, the need to protect public budgets, and other public interest considerations). It provides an excellent comparative study of this complex subject, which lies at the interface between competition law and intellectual property law. The second part of the book gathers contributions from various jurisdictions on the topic of “What rules should govern claims by suppliers about the national or geographic origin of their goods or services?” This section presents an international report, which offers an unparalleled comparative analysis of this topic, bringing together common themes and contrasting the various national provisions dealing with indications of origin, amongst other things. The book also includes the resolutions passed by the General Assembly of the International League of Competition Law (LIDC) following a debate on each of these topics, which include proposed solutions and recommendations. The LIDC is a long-standing international association that focuses on the interface between competition law and intellectual property law, including unfair competition issues.


Antitrust in Pharmaceutical Markets & Geographical Rules of Origin Related Books

Antitrust in Pharmaceutical Markets & Geographical Rules of Origin
Language: en
Pages: 499
Authors: Pierre Kobel
Categories: Law
Type: BOOK - Published: 2017-09-20 - Publisher: Springer

DOWNLOAD EBOOK

This book gathers international and national reports from across the globe on key questions in the field of antitrust and intellectual property. The first part
New Developments in Competition Law and Economics
Language: en
Pages: 358
Authors: Klaus Mathis
Categories: Law
Type: BOOK - Published: 2019-03-18 - Publisher: Springer

DOWNLOAD EBOOK

This book further develops both the traditional and the behavioural approach to competition law, and applies these approaches to a variety of timely issues. It
Private Health Insurance and the European Union
Language: en
Pages: 333
Authors: Cyril Benoît
Categories: Political Science
Type: BOOK - Published: 2020-12-03 - Publisher: Springer Nature

DOWNLOAD EBOOK

Research has paid little attention to date on how European Union law and regulation affect both the public-private mix in healthcare and the organization of pri
Sustainability Objectives in Competition and Intellectual Property Law
Language: en
Pages: 425
Authors: Pranvera Këllezi
Categories: Law
Type: BOOK - Published: 2024-01-13 - Publisher: Springer Nature

DOWNLOAD EBOOK

This open access volume of LIDC contributions focuses on how competition and intellectual property laws incorporate sustainability objectives. Businesses are in
Patent Settlements in the Pharmaceutical Industry under US Antitrust and EU Competition Law
Language: en
Pages: 349
Authors: Amalia Athanasiadou
Categories: Law
Type: BOOK - Published: 2018-08-14 - Publisher: Kluwer Law International B.V.

DOWNLOAD EBOOK

Reverse payment settlements or “pay-for-delay agreements” between originators and generic drug manufacturers create heated debates regarding the balance bet